

ALIVIRA ITALIA S.R.L.
BALANCE SHEET AS AT 31ST MARCH 2023

Particulars	Note No.	As at 31st Mar 2023 (Amount in Euro)	As at 31st Mar 2022 (Amount in Euro)
ASSETS			
1 Non-current assets			
(a) Property, plant and equipment	3	2,825	3,960
(b) Intangible assets	3	4,345	5,113
Total Non-current assets		7,170	9,073
2 Current assets			
(a) Inventories	4	350,743	280,966
(i) Trade receivables	5	561,039	400,099
(ii) Cash and cash equivalents	6	8,830	31,996
(b) Other current assets	7	6,352	6,682
Total Current assets		926,964	719,743
TOTAL ASSETS		934,134	728,816
EQUITY AND LIABILITIES			
1 Equity			
(a) Equity share capital	8	100,000	100,000
(b) Other Equity	9	(284,877)	(224,472)
Retained Earnings		(284,877)	(224,472)
Total Equity		(184,877)	(124,472)
2 Non-Current Liabilities			
(a) Financial Liabilities			
(i) Borrowings	10	95,194	93,391
Total Non-Current Liabilities		95,194	93,391
3 Current liabilities			
(a) Financial Liabilities			
(i) Trade payables	11	998,723	744,627
(b) Other current liabilities	12	12,904	14,249
(c) Current tax liabilities (Net)	13	12,189	1,021
Total Current liabilities		1,023,816	759,897
TOTAL EQUITY AND LIABILITIES		934,134	728,816

The accompanying notes are integral part of these financial statements.

For Alivira Italia S.R.L.

Divyang Adhvaryu

Divyang Adhvaryu
Director
Place: Ferrara, Italy
Date: 15/05/2023

ALIVIRA ITALIA S.R.L.

PROFIT AND LOSS FOR THE PERIOD ENDED AS ON 31ST MARCH 2023

	Particulars	Note No	Year ended March 2023	Year ended March 2022
			(Amount in Euro)	(Amount in Euro)
(I)	Revenue From Operations	14	1,267,735	892,494
(II)	Other Income	15	142,186	136,677
(III)	Total Income (I+ II)		1,409,921	1,029,171
(IV)	EXPENSES			
	Purchases of stock-in-trade	16	1,029,245	720,985
	Changes in inventories of finished goods and work-in-progress & intermediates	17	(69,777)	(87,685)
	Employee benefits expense	18	188,396	119,212
	Finance costs	19	2,999	2,901
	Depreciation and amortization expense	20	3,609	3,504
	Other expenses	21	312,453	300,072
	Total expenses (IV)		1,466,925	1,058,989
(V)	Profit before tax (III-IV)		(57,004)	(29,818)
(VI)	Tax expense:	22		
	(1) Current tax		3,401	-
	(2) Deferred tax		-	-
(VII)	Profit (Loss) for the period (I+II-IV)		(60,405)	(29,818)
(VIII)	Earnings per equity share:	22		
	(1) Basic		(0.60)	(0.30)
	(2) Diluted		(0.60)	(0.30)

For Alivira Italia S.R.L

Divyang Adhvaryu

Director

Place: Ferrara, Italy

Date: 15/05/2023

Alivira Italia S.R.L

Cash Flow Statement for the period ended As at 31 March 2023

Particulars		
	As at 31 March 2023	As at 31 March 2022
A Cash flows from operating activities:		
Profit before tax	(57,004)	(29,818)
Adjustments for:		
Depreciation, Impairment and Amortisation	3,609	3,504
Interest expenses	2,999	2,901
Total	6,608	6,405
Operating profit before working capital changes	(50,396)	(23,413)
Adjustments for:		
Change in trade receivables	(160,941)	(181,088)
Change in inventories	(69,777)	(87,685)
Change in other current assets	330	(6,682)
Change in trade payables	265,469	317,503
Change in other current liabilities	(1,344)	7,575
Total	33,737	49,623
Cash generated from / (used in) operations	(16,659)	26,209
Net cash from operating activities	(16,659)	26,209
B Cash flows from investing activities:		
Purchase of property, plant and equipments	(1,706)	(3,349)
Share capital infusion	-	-
Net cash used in investing activities	(1,706)	(3,349)
C Cash flows from financing activities:		
Proceeds from Long Term Borrowings	(1,803)	1,620
Interest paid	(2,999)	(2,901)
Net cash used in financing activities	(4,802)	(1,281)
Net increase in cash and cash equivalents	(23,166)	21,580
Cash and cash equivalents at the beginning of the year	31,996	10,417
Cash and cash equivalents at the end of the year	8,830	31,996

(0)

1

Reconciliation of cash and cash equivalents with the Balance sheet

Cash on Hand	123	813
Balance with banks	8,707	31,183
Cash and Cash equivalents as per balance sheet (Refer note 8)	8,830	31,996

For Alivira Italia S.R.L



Divyang Adhvaryu
 Director
 Place: Ferrara, Italy
 Date: 15/05/2023

Alivira Italia S.R.L.
Statement of Changes in Equity (SOCIE) for the year ended 31. March 2023
Amounts in Euros (€) unless otherwise stated

	As at 31 March 2023		As at 31 March 2022	
	No. of Shares	Amount	No. of Shares	Amount
(a) Equity share capital	100,000	100,000	100,000	100,000
Balance at the beginning of the reporting year				
Balance at the end of the reporting year	100,000	100,000	100,000	100,000

Particulars	Reserves and Surplus			Total
	General reserve	Securities Premium	Retained Earnings	
Balance at 01 April 2021	-	-	(194,653)	(194,653)
Profit for the year	-	-	(29,818)	(29,818)
Balance at 31 March 2022	-	-	(224,472)	(224,472)
Profit for the year	-	-	(60,405)	(60,405)
Balance at 31 March 2023	-	-	(284,877)	(284,877)

The accompanying notes are an integral part of the financial statements.
For Alivira Italia S.R.L.



Divyang Advharyu
Director
Place: Ferrara, Italy
Date: 15/05/2023

Note

1 Legal status and principal activities

Alivira Italia S.R.L. is a limited liability company having its registered office in Ferrara, Italy. The company is mainly into production and distribution of pharmaceutical, nutraceuticals additives for feed, chemical and disinfectant products both Finished product and active ingredient for use of Veterinary.

2 Significant accounting policies

2.1 Basis of accounting and preparation of financial statements

Alivira Italia S.R.L.'s annual financial statement as of March 31st, 2023 was drawn up pursuant to The financial statements have been prepared in accordance with The Italian Civil Code and consist of the balance sheet (prepared in the format required by Articles 2424 and 2424 bis of the Italian Civil Code), the income statement (prepared in the format required by Articles 2425 and 2425 bis of the Italian Civil Code) and these notes. The notes contain the information required by Article 2427 of the Italian Civil Code, by other provisions of Legislative Decree no 127/91 and other legal provisions.

2.2 Tangible fixed assets

Fixed assets are carried at cost less accumulated depreciation and impairment losses, if any. The cost of fixed assets comprise its purchase price net of any trade discounts and rebates, any import duties and other taxes (other than the subsequently recoverable from the tax authorities), any directly attributable expenditure on making the asset ready for its intended use, other incidental expenses and interest on borrowings attributable to acquisition of qualifying fixed assets to the date the asset is ready for its intended use. Exchange differences arising on restatement/ settlement of long-term foreign currency borrowings relating to acquisition of depreciable fixed assets are adjusted to the cost of the respective assets and depreciated over the remaining useful life of such assets. Subsequent expenditure relating to fixed assets is capitalised only if such expenditure results in an increase in the future benefits from such asset beyond its previously assessed standard of performance.

2.3 Depreciation

Depreciation is provided under the straight-line method based on the useful lives:

Nature of Asset	Useful life in periods (range)
Computers	5 Years
Marketing Authorisations	5 Years

2.4 Impairment of assets

The carrying values of assets / cash generating units at each balance sheet date are reviewed for impairment if any indication of impairment exists. The following intangible assets are tested for impairment each financial period even if there is no indication that the asset is impaired:
(a) an intangible asset that is not yet available for use; and (b) an intangible asset that is amortised over a period exceeding ten periods from the date when the asset is available for use.

If the carrying amount of the assets exceed the estimated recoverable amount, an impairment is recognised for such excess amount. The impairment loss is recognised as an expense in the Statement of Profit and Loss, unless the asset is carried at revalued amount, in which case any impairment loss of the revalued asset is treated as a revaluation decrease to the extent a revaluation reserve is available for that asset.

The recoverable amount is the greater of the net selling price and their value in use. Value in use is arrived at by discounting the future cash flows to their present value based on an appropriate discount factor.

When there is indication that an impairment loss recognised for an asset (other than a revalued asset) in earlier accounting periods no longer exists or may have decreased, such reversal of impairment loss is recognised in the Statement of Profit and Loss, to the extent the amount was previously charged to the Statement of Profit and Loss. In case of revalued assets such reversal is not recognised.

2.4 Inventory

Inventories comprises of finished goods. These are valued at the lower of cost and net realizable value. Cost is determined on First in First out basis for finished goods - 'At material cost, conversion costs and an appropriate share of production overheads.

2.5 Revenue recognition

Revenue from export sales is recognized on the basis of the shipping bills for exports. Revenue from domestic sales is recognized based on the passage of title of goods which generally coincides with dispatch. Sales are stated net of discounts, other taxes, and sales returns.

Dividend income is recognised when the right to receive the same is established.

Interest income is recognised on an accrual basis.

2.6 Employee benefits

Short term employee benefits are accrued based on the terms of employment when services are rendered by the employees and charged as an expense to the statement of profit and loss.

Leave balances standing to the credit of the employees that are expected to be availed in the short term are provided for on full cost basis.

2.7 Foreign currency transactions

Initial recognition

Transactions in foreign currencies entered into by the Company are accounted at the exchange rates prevailing on the date of the transaction or at rates that closely approximate the rate at the date of the transaction.

Measurement at the Balance Sheet date

Foreign currency monetary items of the Company outstanding at the Balance Sheet date are restated at the period-end rates. Non monetary items of the Company are carried at historical cost. Revenue and expenses are translated at the average exchange rates prevailing during the period.

Treatment of exchange differences

Exchange differences arising on settlement / restatement of foreign currency monetary assets and liabilities of the Company are recognised as income or expense in the statement of profit and loss.

2.8 Taxes on Income

Income Tax comprises the current tax provision. Current tax is the amount of tax payable on the taxable income for the period.

2.9 Earnings per share (EPS)

In determining the Earnings per share, the Company considers the net profit after tax. The number of shares used in computing Basic Earnings per share is the weighted average number of equity shares outstanding during the period. The number of shares used in computing Diluted Earnings per share comprises the weighted average number of equity shares considered for deriving Basic earnings per share and also the weighted average number of equity shares that could have been issued on the conversion of all dilutive potential equity shares. Dilutive potential equity shares are deemed converted as of the beginning of the period unless issued at a later date.

2.10 Provisions and contingencies

A provision is recognized when the Company has a present legal or constructive obligation as a result of past event and it is probable that an outflow of resources will be required to settle the obligation, in respect of which reliable estimate can be made. Provisions (excluding retirement benefits) are not discounted to its present value and are determined based on best estimate required to settle the obligation at the balance sheet date. These are reviewed at each balance sheet date and adjusted to reflect the current best estimate. Contingent liabilities are not recognized but are disclosed in the notes to financial statements.

2.11 Use of estimates

The preparation of the financial statements in conformity with the Accounting Standards generally accepted in India requires that the Management makes estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent liabilities as at the date of the financial statements and the reported amounts of revenue and expenses during the reported period. Management believes that the estimates used in preparation of financial statement are prudent and reasonable. Actual results could differ from those estimates and the estimates are recognised in the period in which the results are known/materialise.

2.12 Segment

Segments have been identified taking into account the nature of operations, the differing risks and returns, the organizational structure and the internal reporting system.

2.13 Insurance claims

Insurance claims are accounted for on the basis of claims admitted / expected to be admitted and to the extent that there is no uncertainty in receiving the claims.

2.13 Borrowing costs

Borrowing costs include interest, amortisation of ancillary costs incurred and exchange differences arising from foreign currency borrowings to the extent they are regarded as an adjustment to the interest cost. Costs in connection with the borrowing of funds to the extent not directly related to the acquisition of qualifying assets are charged to the Statement of Profit and Loss over the tenure of the loan.

2.14 Cash flow statement

Cash flows are reported using the indirect method, whereby profit / (loss) before extraordinary items and tax is adjusted for the effects of transactions of non-cash nature and any deferrals or accruals of past or future cash receipts or payments. The cash flows from operating, investing and financing activities are segregated based on the available information.

2.14 Cash and cash equivalents (for purposes of cash flow statement)

Cash and cash equivalents in the balance sheet comprise cash at banks and on hand and short-term deposits with an original maturity of three months or less, which are subject to an insignificant risk of changes in value.

2.15 Leases

Ind AS 116 supersedes Ind AS 17 Leases. The standard sets out the principles for the recognition, measurement, presentation and disclosure of leases and requires lessees to recognise most leases on the balance sheet.

The Company adopted Ind AS 116 using the modified retrospective method of adoption with the date of initial application of 01 April 2019. Under this method, the standard is applied retrospectively with the cumulative effect of initially applying the standard recognised at the date of initial application.

Leases previously accounted for as operating leases

The Company recognised right-of-use assets and lease liabilities for those leases previously classified as operating leases, except for short-term leases and leases of low-value assets. The right-of-use assets for most leases were recognised based on the carrying amount as if the standard had always been applied, apart from the use of incremental borrowing rate at the date of initial application. In some leases, the right-of-use assets were recognised based on the amount equal to the lease liabilities, adjusted for any related prepaid and accrued lease payments previously recognised. Lease liabilities were recognised based on the present value of the remaining lease payments, discounted using the incremental borrowing rate at the date of initial application. The Right of Use asset are depreciated on a straight - line basis over the lease term.

The Company also applied the available practical expedients wherein it:

- Used a single discount rate to a portfolio of leases with reasonably similar characteristics,
- Relied on its assessment of whether leases are onerous immediately before the date of initial application,
- Applied the short-term leases exemptions to leases with lease term that ends within 12 months of the date of initial application,
- Excluded the initial direct costs from the measurement of the right-of-use asset at the date of initial application,
- Used hindsight in determining the lease term where the contract contained options to extend or terminate the lease.

2.16 Operating Cycle

Based on the nature of products / activities of the Company and the normal time between acquisition of assets and their realisation in cash or cash equivalents, the Company has determined its operating cycle as 12 months for the purpose of classification of its assets and liabilities as current and non-current.

ALIVIRA ITALIA S.R.L.

Notes forming part of the financial statements for the year ended 31 March 2023

All amounts are in Euros

Note 3: Property, plant and equipment & Intangible assets

Particulars	As at 31 March, 2023	As at 31 March, 2022
Carrying Amount of:		
Office Equipments	2,825	3,960
Patent Rights & Software	4,345	5,113
Total	7,170	9,073

Particulars	Office Equipments	Patent Rights & Software
Cost or deemed cost		
Balance as on 01 April, 2021	6,473	6,059
Assets acquired	548	2,800
Balance as on 31 March, 2022	7,021	8,859
Assets acquired	300	1,406
Balance as on 31 March, 2023	7,321	10,265

Particulars	Office Equipments	Patent Rights & Software
Accumulated depreciation and impairment		
Balance as on 01 April, 2021	1,712	1,591
Depreciation / amortisation expense for the year	1,349	2,155
Balance as on 31 March, 2022	3,061	3,746
Depreciation / amortisation expense for the year	1,434	2,175
Balance as on 31 March, 2023	4,495	5,921

Particulars	Office Equipments	Patent Rights & Software
Carrying amount		
Balance as on 31 March, 2022	3,960	5,113
Balance as on 31 March, 2023	2,825	4,345

Note 4	Inventories	As at 31 March 2023	As at 31 March 2022
	Stock-in-trade	350,743	280,966
	Total	350,743	280,966
	Note:		
	During the year ended 31 March 2023, EUR 14274 (31 March 2022 : NIL) was recognised as an expense towards provision for slow moving, expired and near expiry inventories.		

Note no	Particulars	As at 31st Mar 2023 (Amount in Euro)	As at 31st Mar 2022 (Amount in Euro)
	Financial Assets		
5	Trade receivables		
	(a) Unsecured, considered good	561,039	400,099
	Less: Provision for doubtful debts	-	-
		561,039	400,099
6	Cash and cash equivalents		
	Cash on hand	123	813
	Balances with banks	-	-
	- In current accounts	8,707	31,183
		8,830	31,996

Note 7	Other Current Assets	As at 31 March 2023	As at 31 March 2022
	Advance to Suppliers	6,352	330
	Others	-	6,352
		6,352	6,682

Trade Receivables
As on 31 March 2023

	Not due	Less than 6 months	6 months - 1 years	1-2 years	2-3 years	More than 3 years	Total
(i) Undisputed Trade Receivables - considered good	509,972	34,805	16,262				561,039
(ii) Undisputed Trade Receivables - considered doubtful							-
(iii) Disputed Trade Receivables - considered good							-
(iv) Disputed Trade Receivables - considered doubtful							-
Total	509,972	34,805	16,262	-	-	-	561,039

As on 31 March 2022

	Not due	Less than 6 months	6 months - 1 years	1-2 years	2-3 years	More than 3 years	Total
(i) Undisputed Trade Receivables - considered good	381,209	18,890					400,099
(ii) Undisputed Trade Receivables - considered doubtful							-
(iii) Disputed Trade Receivables - considered good							-
(iv) Disputed Trade Receivables - considered doubtful							-
Total	381,209	18,890	-	-	-	-	400,099

Trade Payables

As on 31 March 2023

	Unbilled	Not Due	Less than 1 year	1-2 years	2-3 years	More than 3 years	Total
(i) Undisputed dues	51,399	410,169	268,702	189,499	78,954		998,723
(ii) Disputed dues							-
	51,399	410,169	268,702	189,499	78,954	-	998,723

As on 31 March 2022

	Unbilled	Not Due	Less than 1 year	1-2 years	2-3 years	More than 3 years	Total
(i) Undisputed dues	23,098	393,051	219,415	109,063			744,627
(ii) Disputed dues							-
	23,098	393,051	219,415	109,063	-	-	744,627

ALIVIRA ITALIA S.R.L.
Notes to the financial statements for the period ended 31 Mar 2023
All amounts are in EUR unless otherwise stated

Note 7 Share capital

	As at 31 March 2023		As at 31 March 2022	
	No. of Shares	Rs.	No. of Shares	Rs.
(a) Authorised 100000 Shares of 1 EUR each.	100,000	100,000	100,000	100,000
	100,000	100,000	100,000	100,000
(b) Issued, subscribed and fully paid-up 100000 Shares of 1 EUR each.	100,000	100,000	100,000	100,000
Total		<u>100,000.00</u>		<u>100,000.00</u>

Notes:

(i) Reconciliation of the number of shares and amount outstanding

	No. of Shares	Share capital
Fully paid equity shares		
Balance as on 1 April 2021	100,000	100,000.00
Balance as on 31 March 2022	100,000	100,000.00
Share issued during the year	-	-
Balance as on 31 March 2023	100,000	100,000.00

(ii) Details of shares held by holding company

	As at 31 March 2023			As at 31 March 2022		
Name of the shareholder	No. of shares held	% of holding	No. of shares held	% of holding	No. of shares held	% of holding
Alivira Animal Health Limited, Ireland	95,000	95%	95,000	95%	95,000	95%
Renzo Rimondi	3,750	4%	3,750	4%	3,750	4%
Ramon Vila Vina	1,250	1%	1,250	1%	1,250	1%

(iv) Details of shares held by each shareholder holding more than 5% shares

	As at 31 March 2023			As at 31 March 2022		
Name of the shareholder	No. of shares held	% of holding	No. of shares held	% of holding	No. of shares held	% of holding
Alivira Animal Health Limited, Ireland	95,000	95%	95,000	95%	95,000	95%

(v) Aggregate number of shares allotted as fully paid pursuant to contract without payment of cash for a period of 5 years immediately preceding the balance sheet date:

Equity shares	As at 31 March 2023	As at 31 March 2022
	NIL	NIL

ALIVIRA ITALIA S.R.L.

Notes to accounts

Note no	Particulars	As at	As at
		31st Mar 2023	31st Mar 2022
		(Amount in Euro)	(Amount in Euro)
9	a) Retained Earnings		
	Opening Balance	(297,175)	(194,653)
	Add: Profit / (Loss) for the year	12298.51	-29818.84
		<u>(284,877)</u>	<u>(224,472)</u>
	Other Equity (Total)	<u>(284,877)</u>	<u>(224,472)</u>
10	Non-current liabilities - Financial Liabilities - Long term borrowings		
	From other parties		
	Unsecured	95,194	93,391
		<u>95,194</u>	<u>93,391</u>
11	Trade payable		
	Trade payable	967,480	732,980
	Employee Payables	31,242	11,647
		<u>998,723</u>	<u>744,627</u>
12	Other Current Liabilities		
	Other Current Liabilities	12,904	14,249
		<u>12,904</u>	<u>14,249</u>
13	Current tax liabilities (Net)		
	Withholding TAXES (Payable) / Recoverable	12,189	1,021
		<u>12,189</u>	<u>1,021</u>

ALIVIRA ITALIA S.R.L.

Notes to accounts

Note no	Particulars	Year ended	Year ended
		March 2023	March 2022
		(Amount in Euro)	(Amount in Euro)
14	Revenue from operations		
	a) Sale of products	1,406,647	978,878
	b) Commission on sales	(138,912)	(86,384)
		<u>1,267,735</u>	<u>892,494</u>
15	Other Income		
	Other Non-operating Income	142,186	136,677
		<u>142,186</u>	<u>136,677</u>
16	Purchases of stock-in-trade		
	Purchases of stock-in-trade	1,029,245	720,985
		<u>1,029,245</u>	<u>720,985</u>
17	Changes in inventories of finished goods and work-in-progress & intermediates		
	Opening stock	280,966	193,281
		<u>280,966</u>	<u>193,281</u>
	Finished goods	350,743	280,966
		<u>350,743</u>	<u>280,966</u>
	Net (increase) / decrease	<u>(69,777)</u>	<u>(87,685)</u>
18	Employee benefits expense		
	Salaries and wages	188,396	119,212
		<u>188,396</u>	<u>119,212</u>
19	Finance costs		
	Interest expense (Borrowing Int on Loan from Group Co)	1,620	1,620
	Other borrowing costs	1,379	1,281
		<u>2,999</u>	<u>2,901</u>
20	Depreciation and amortization expense		
	Tangible assets	1,434	1,349
	Intangible assets	2,175	2,155
		<u>3,609</u>	<u>3,504</u>
21	Other expenses		
	Travel expenses	-	52,744
	Communication expenses	-	527
	Admin Expenses	21,892	28,606
	Legal and Professional charges	201,797	197,661
	Freight and forwarding	74,006	-
	Advertisement and selling expenses	5,465	4,973
	Other expenses	3,912	15,561
		<u>312,453</u>	<u>300,072</u>
22	Tax expense		
	Current tax	3,401	-
		<u>3,401</u>	<u>-</u>

ALIVIRA ITALIA S.R.L.

Notes to the financial statements for the year ended 31 March 2023

Amounts in Euros (€) unless otherwise stated

22 Earnings per share

Particulars	Year ended 31 March 2023	Year ended 31 March 2022
Net profit / (loss) for the year as per statement of profit and loss	(60,405)	(29,818)
Weighted average number of equity shares	100,000	100,000
Earnings / (Loss) per share - Basic	(0.60)	(0.30)
Earnings / (Loss) per share - Diluted	(0.60)	(0.30)

23 Contingent liabilities and commitments

There are no contingent liability and commitments as at 31 March 2023. (31 March 2022 - Nil)

24 Segment Reporting

A. Primary segment (Business segment)

The Company is mainly engaged in the business of pharmaceuticals. Considering the nature of business and financial reporting of The Company, The Company has only one business segment viz; pharmaceuticals as primary reportable segment.

B. Secondary segment (Geographical segment)

The Company operates in three principal geographic location.

- (i) Europe
- (ii) Asia
- (iii) Rest of the world

	Year ended 31 March 2023	Year ended 31 March 2022
I Revenue from operations		
Europe	1,267,735	892,494
Total	1,144,527	892,494
II Total assets		
Europe	934,134	728,816
Total segment assets	934,134	728,816
Total	934,134	728,816

25

Financial instruments

The carrying value / fair value of financial instruments by categories are as follows:

	Carrying value and fair value	
	31 March 2023	31 March 2022
Financial assets		
Measured at amortised cost		
Loans	-	-
Trade receivables	561,039.31	400,098.62
Cash and cash equivalents	8,829.76	31,996.08
Total	569,869.07	308,886.51
Financial liabilities		
Measured at amortised cost		
Borrowings (including current maturity of long-term borrowings)	95,194.35	93,391.36
Trade payables	998,722.51	744,627.18
Total	1,093,916.86	838,018.54

25.1 Financial risk management objective and policies

The Company's principal financial liabilities comprise loans and borrowings, trade payables and other payables. The main purpose of these financial liabilities is to finance The Company's operations. The Company's principal financial assets include investments, loans, trade and other receivables, and cash and deposits that derive directly from its operations.

The Company is exposed to the following risks from its use of financial instruments:

- Credit risk
- Liquidity risk
- Market risk

This note presents information about The Company's exposure to each of the above risks, The Company's objectives, policies and processes for measuring and managing risk, and The Company's management of capital. Further quantitative disclosures are included throughout these consolidated financial statements.

Risk management framework

25.2 Credit risk

Credit risk is the risk of financial loss to The Company if a customer or counterparty to a financial instrument fails to meet its contractual obligations resulting in a Given below is ageing of trade receivable spread by period of six months:

	31 March 2022	31 March 2021
Outstanding for more than 6 months	-	-
Others	400,099	219,010
Total	400,098.62	219,010.23

The Company continuously monitors defaults of customers and other counterparties, identified either individually or by The Company, and incorporates this information into its credit risk controls.

The Company limits its exposure to credit risk by generally investing in liquid securities and only with counterparties that have a good credit rating.

Trade receivables consist of a large number of customers spread across diverse industries and geographical areas. Ongoing credit evaluation is performed on the financial condition of accounts receivable and where appropriate, credit guarantee insurance cover is purchased for export customers.

25.3 Liquidity risk

Liquidity risk is the risk that The Company will encounter difficulty in meeting the obligations associated with its financial liabilities that are settled by delivering cash or another financial asset. The Company approach to managing liquidity is to ensure, as far as possible, that it will always have sufficient liquidity to meet its liabilities when due, under both normal and stressed conditions, without incurring unacceptable losses or risking damage to The Company reputation.

The Company has an appropriate liquidity risk management framework for the management of short, medium and long term funding and liquidity management requirements. The Company manages liquidity risk by maintaining adequate cash reserves, banking facilities and reserve borrowing facilities by continuously monitoring forecast and actual cash flows and matching the maturity profiles of financial assets and liabilities.

The Company's treasury department is responsible for managing the short-term and long-term liquidity requirements of The Company. Short-term liquidity situation is reviewed daily by treasury. Long-term liquidity position is reviewed on a regular basis by the Board of Directors and appropriate decisions are taken according to the situation.

Typically, The Company ensures that it has sufficient cash on demand to meet expected operational expenses for a period of 60 days, including the servicing of financial obligations; this excludes the potential impact of extreme circumstances that cannot reasonably be predicted, such as natural disasters.

The table below provides details regarding the contractual maturities of significant financial liabilities as at 31 March 2023 and 31 March 2022:

Particulars	As at 31 March 2023		
	Less than 1 year	1-2 years	2 years and above
Borrowings (including current maturity of long-term borrowings and judicial recovery)		95,194.35	95,194.35
Trade payables	730,270.00	189,499.00	998,723.00
Particulars	As at 31 March 2022		
	Less than 1 year	1-2 years	2 years and above
Borrowings (including current maturity of long-term borrowings and judicial recovery)	-	-	93,391.36
Trade payables	635,564.18	109,063.00	744,627.18

25.4 Capital management

For the purpose of The Company's capital management, capital includes issued equity capital and all other equity reserves attributable to the equity share holders of The Company. The primary objective of The Company's capital management is to maximise the shareholder value.

The Company manages its capital structure and makes adjustments in light of changes in economic conditions and the requirements of the financial covenants. To maintain or adjust the capital structure, The Company may adjust the dividend payment to shareholders, return capital to shareholders or issue new shares. The Company monitors capital using a gearing ratio, which is net debt divided by total capital plus net debt. The Company includes within net debt, interest bearing loans and borrowings less cash and cash equivalents

In order to achieve this overall objective, The Company's capital management, amongst other things, aims to ensure that it meets financial covenants attached to the interest-bearing loans and borrowings that define capital structure requirements. Breaches in meeting the financial covenants would permit the bank to immediately call loans and borrowings. As at 31 March 2021, there is no breach of covenant attached to the borrowings.

The Company manages its capital to ensure that entities in The Company will be able to continue as going concerns while maximising the return to stakeholders through the optimisation of the debt and equity balance.

The capital structure of The Company consists of net debt (offset by cash and bank balances) and total equity of The Company.

The Company's gearing ratio at end of each reporting year is as follows:

	31 March 2023	31 March 2022
Debt (i)	95,194.35	93,391.36
Cash and bank balances (ii)	8,829.76	31,996.08
Net debt [(i) - { (ii)+(iii)+(iv) }]	86,364.59	61,395.28
Equity attributable to owners of the Company	(184,876.75)	(124,472.04)
Gearing ratio	0.00%	0.00%

(i) Debt is defined as long-term (including current maturity on long-term borrowings), short-term borrowings.

(ii) Other bank balance exclude the bank balance towards unpaid dividend.

(iii) Gearing ratio : Net debt / Equity.

ALIVIRA ITALIA S.R.L.

Notes to the financial statements for the year ended 31 March, 2023

Amounts in Euros (€) unless otherwise stated

26

Related Party Disclosures:

A List of related parties:

i) Holding company:

Alivira Animal Health Limited, Ireland
 Alivira Animal Health Limited, India (Holding company of Alivira Animal Health Limited, Ireland)
 Sequent Scientific Limited, India (Ultimate Holding Company)

ii) Fellow subsidiary:

Laboratorios Karizoo S.A
 Phytotherapeutic solutions S.L.

A. Transaction during the period

Nature of Transactions	Holding Company		Fellow Subsidiary	
	As at 31 March 2023	As at 31 March 2022	As at 31 March 2023	As at 31 March 2022
(i) Purchases				
Laboratorios Karizoo S.A			584,481	386,876
Alivira Animal Health Limited, Ireland	102,750	-	-	-
Phytotherapeutic solutions S.L.			235	9,369
(ii) Professional/ Support Charges				
Alivira Animal Health Limited, Ireland	173,811	159,380	18,073	7,079
Laboratorios Karizoo S.A				
(iii) Loan Taken during the year				
Alivira Animal Health Limited, Ireland				
(iv) Interest Paid				
Alivira Animal Health Limited, Ireland	1,620	1,620		
(V) Other Income				
Phytotherapeutic solutions S.L.			142,032	118,603

B. Balance as at balance sheet date:

Nature of Transactions	Holding Company		Fellow Subsidiary	
	As at 31 March 2023	As at 31 March 2022	As at 31 March 2023	As at 31 March 2022
(i) Receivable Balance Phytotherapeutic Solutions S.L.			11,000	365
(ii) Payable balance Alivira Animal Health Limited, Ireland Laboratorios Karizoo S.A	465,064	268,453	299,032	266,067
(ii) Loan Outstanding Alivira Animal Health Limited, Ireland	95,194	93,574		

For Alivira Italia S.R.L



Diwyang Adhvaryu
Director
Place: Ferrara, Italy
Date: 15/05/2023